[HTML][HTML] Rethinking the role of hydroxychloroquine in the treatment of COVID‐19
EA Meyerowitz, AGL Vannier, MGN Friesen… - The FASEB …, 2020 - ncbi.nlm.nih.gov
There are currently no proven or approved treatments for coronavirus disease 2019 (COVID‐
19). Early anecdotal reports and limited in vitro data led to the significant uptake of …
19). Early anecdotal reports and limited in vitro data led to the significant uptake of …
[HTML][HTML] Remdesivir in patients with acute or chronic kidney disease and COVID-19
ML Adamsick, RG Gandhi, MR Bidell… - Journal of the …, 2020 - journals.lww.com
On May 1, 2020, after review of yet unpublished data from available clinical trials, the US
Food and Drug Administration issued an emergency use authorization (EUA) to permit the …
Food and Drug Administration issued an emergency use authorization (EUA) to permit the …
Coinfection with HIV-1 and HCV—a one-two punch
AY Kim, RT Chung - Gastroenterology, 2009 - Elsevier
Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, cirrhosis, and
death; it is estimated that 180 million persons are infected with HCV worldwide. The …
death; it is estimated that 180 million persons are infected with HCV worldwide. The …
[HTML][HTML] Efficacy of tocilizumab in patients hospitalized with Covid-19
JH Stone, MJ Frigault, NJ Serling-Boyd… - … England Journal of …, 2020 - Mass Medical Soc
Background The efficacy of interleukin-6 receptor blockade in hospitalized patients with
coronavirus disease 2019 (Covid-19) who are not receiving mechanical ventilation is …
coronavirus disease 2019 (Covid-19) who are not receiving mechanical ventilation is …
[PDF][PDF] The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection
Although 20%‐40% of persons with acute hepatitis C virus (HCV) infection demonstrate
spontaneous clearance, the time course and factors associated with clearance remain …
spontaneous clearance, the time course and factors associated with clearance remain …
[PDF][PDF] Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment‐naive patients
Resistance mutations to hepatitis C virus (HCV) nonstructural protein 3 (NS3) protease
inhibitors in< 1% of the viral quasispecies may still allow> 1000‐fold viral load reductions …
inhibitors in< 1% of the viral quasispecies may still allow> 1000‐fold viral load reductions …
Nirmatrelvir plus ritonavir for early COVID-19 in a large US health system: a population-based cohort study
S Dryden-Peterson, A Kim, AY Kim… - Annals of internal …, 2023 - acpjournals.org
Background: In the EPIC-HR (Evaluation of Protease Inhibition for Covid-19 in High-Risk
Patients) trial, nirmatrelvir plus ritonavir led to an 89% reduction in hospitalization or death …
Patients) trial, nirmatrelvir plus ritonavir led to an 89% reduction in hospitalization or death …
[HTML][HTML] Temporal and spatial heterogeneity of host response to SARS-CoV-2 pulmonary infection
The relationship of SARS-CoV-2 pulmonary infection and severity of disease is not fully
understood. Here we show analysis of autopsy specimens from 24 patients who succumbed …
understood. Here we show analysis of autopsy specimens from 24 patients who succumbed …
CD8 epitope escape and reversion in acute HCV infection
J Timm, GM Lauer, DG Kavanagh, I Sheridan… - The Journal of …, 2004 - rupress.org
In the setting of acute hepatitis C virus (HCV) infection, robust HCV-specific CD8+ cytotoxic T
lymphocyte (CTL) responses are associated with initial control of viremia. Despite these …
lymphocyte (CTL) responses are associated with initial control of viremia. Despite these …
High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection
Background & Aims: Cellular immune responses are thought to play a key role in the
resolution of primary HCV infection. Although it has been consistently shown that CD4+ T …
resolution of primary HCV infection. Although it has been consistently shown that CD4+ T …